22.07.2015 • News

Pfizer Ranked Top Foreign Firm in UK Academic Research

US drugmaker Pfizer has more collaborations with British universities than any other foreign company, according to the newly published Dowling Review conducted by Ann Dowling, president of the Royal Academy of Engineering.

The business daily Financial Times (FT) commented that the review sheds new light on Pfizer’s role in the UK science base a year after it was defeated in a bitter battle to buy AstraZeneca. It recalls that fears Pfizer would cut jobs and scrap research at the UK pharmaceuticals group fueled political opposition to the proposed £69.4 billion deal.

In the discussion about Pfizer’s grab for AstraZeneca, the US company’s commitment to the UK was questioned. It was pointed out that the drugmaker cut thousands of jobs four years earlier at its former research and development center in Sandwich, Kent, where the blockbuster erectile dysfunction treatment Viagra was discovered.

Pfizer said it was proud that its support for “world class science in the UK” had been recognized by the review. Analysts have speculated that the pharmaceutical giant, still flush with cash, may return to Britain for another raid on one of the country’s biggest drugs groups, possibly Glaxo SmithKline (GSK).

According to the Dowling Review, two-thirds of the 40 companies with the greatest number of collaborations with UK universities are based overseas. In pharmaceuticals, these include Bayer and Roche.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read